VHL Antibody - N-terminal region : Biotin (ARP59367_P050-Biotin)

Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.

ELC1; HIF1A; UBC; TPT1; MDFI; USP33; KAT2B; E2F1; TCP1; HSP90AA1; HSPA4; GLI1; EP300; SIRT1; AURKA; PARK7; RBX1; PDCD5; CUL2; TCEB2; TCEB1; AR; PIAS4; ILF3; HNRNPL; HNRNPA2B1; PRMT1; PRMT8; SON; SLC3A2; SLC2A1; RPS15A; RPL21; RPL5; HIST4H4; ACTB; VAPB; HI

All conjugated antibodies should be stored in light-protected vials or covered with a light protecting material (i.e. aluminum foil) . Conjugated antibodies are stable for at least 12 months at 4C. If longer storage is desired (24 months), conjugates may be diluted with up to 50% glycerol and stored at -20C to -80C. Freezing and thawing conjugated antibodies will compromise enzyme activity as well as antibody binding.